Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses the effects of approving atezolizumab, an anti-PD-L1 monoclonal antibody, in resected non-small cell lung cancer (NSCLC). Atezolizumab has increased the efficacy of surgical resection by improving patient outcomes receiving surgery, and in the IMpower010 trial (NCT02486718), patients with tumors expressing PD-L1 on more than 50% of tumor cells had the most benefit. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).

свернуть